Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Prenetics Global Limited Class A Ordinary Share (PRE)

Prenetics Global Limited Class A Ordinary Share (PRE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Prenetics Global Limited Class A Ordinary Share Unit 703-706 K11 Atelier King's Road 728 King's Road Quarry Bay K3 00000 HKG

www.prenetics.com Employees: 285

Sector:

Medical

Description:

Prenetics, a leading genomics-driven health sciences company, is revolutionizing prevention, early detection, and treatment. Their prevention arm, CircleDNA, uses whole exome sequencing to offer the world's most comprehensive consumer DNA test. Insighta, their joint venture with renowned scientist Prof. Dennis Lo, underscores their unwavering commitment to saving lives through pioneering multi-cancer early detection technologies. Lastly, ACT Genomics, their treatment unit, is the first Asia-based company to achieve FDA clearance for comprehensive genomic profiling of solid tumors via ACTOnco. Each of Prenetics' units synergistically enhances their global impact on health, truly embodying their commitment to 'enhancing life through science'.

Key Statistics

Overview:

Market Capitalization, $K 284,561
Enterprise Value, $K 232,311
Shares Outstanding, K 16,828
Annual Sales, $ 30,620 K
Annual Net Income, $ -46,300 K
Last Quarter Sales, $ 23,560 K
Last Quarter Net Income, $ -7,410 K
EBIT, $ -43,430 K
EBITDA, $ -37,500 K
60-Month Beta 0.35
% of Insider Shareholders 7.80%
% of Institutional Shareholders 25.01%
Float, K 15,515
% Float 92.20%
Short Interest 108
Short Float 0.64%
Short Volume Ratio 0.36

Growth:

1-Year Return 192.92%
3-Year Return -43.63%
5-Year Return 0.00%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.41 on 11/10/25
Next Earnings Date 04/29/26
Earnings Per Share ttm -2.03
EPS Growth vs. Prev Qtr 50.00%
EPS Growth vs. Prev Year 51.19%
Annual Dividend & Yield 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Next Ex-Dividends Date 02/17/16
Dividend Payable Date 12/19/14
Dividend Payout Ratio 0.00%
Most Recent Split 1-15 on 11/14/23

PRE Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -30.12%
Return-on-Assets % -23.87%
Profit Margin % -151.21%
Debt/Equity 0.00
Price/Sales 9.40
Price/Cash Flow N/A
Price/Book 1.79
Book Value/Share 9.58
Interest Coverage -0.10
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar